Histone Post-translational Modifications in Huntington’s and Parkinson’s Diseases

E-ISSN： 1873-4286|19|28|5085-5092

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.19, Iss.28, 2013-04, pp. : 5085-5092

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Developing a neuroprotective therapy for Parkinson’s and Huntington’s diseases

By Kazantsev Aleksey G

Expert Opinion on Therapeutic Patents, Vol. 17, Iss. 2, 2007-02 ,pp. : 159-172

Informa Healthcare

Access to resources Recommend Favorite

Histone Post-translational Modifications to Target Memory-related Diseases

Current Pharmaceutical Design, Vol. 19, Iss. 28, 2013-04 ,pp. : 5065-5075

Bentham Science Publishers

Access to resources Recommend Favorite

Cholinergic System and Post-translational Modifications: An Insight on the Role in Alzheimer#39;s Disease

Current Neuropharmacology, Vol. 15, Iss. 4, 2017-04 ,pp. : 480-494

Bentham Science Publishers

Access to resources Recommend Favorite

Post-Translational Protein Modifications of Rare and Unconventional Types: Implications in Functions and Diseases

Current Medicinal Chemistry, Vol. 23, Iss. 7, 2016-02 ,pp. : 714-745

Bentham Science Publishers

Access to resources Recommend Favorite

GABA signalling: therapeutic targets for epilepsy, Parkinson’s disease and Huntington’s disease

By Kleppner S.R. Tobin A.J.

Expert Opinion on Therapeutic Targets, Vol. 5, Iss. 2, 2001-04 ,pp. : 219-239

Informa Healthcare

Access to resources Recommend Favorite